Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.
Healthcare Asia on MSN3d
Saudi healthcare research centre to combat diabetic retinopathy in new partnershipThe collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...
Hosted on MSN5d
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialOcugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...
Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...
AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.
Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.
Ip MS. Update on the current treatment of diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback